Recon: Lilly to buy Sigilon Therapeutics; FDA adcomm recommends approval of Ipsen’s fibrodysplasia drug

• Biotech firm Tevogen Bio enters $1.2 billion SPAC deal for US listing (Reuters)
• Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments (Reuters)
• US abortion pill access could hinge on whether doctors had right to sue (Reuters)
• US CDC OKs use of new Pfizer, GSK vaccines for RSV in older adults (Reuters)
• BioXcel shares plunge after issues at trial site for Alzheimer's-related drug (Reuters)
• Pfizer-OPKO's growth hormone drug gets US approval in kids (Reuters)
• Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep (Bloomberg)
• FDA adcomm votes in favor of Ipsen's fibrodysplasia drug (Endpoints)
• FDA plots challenges in implementing new laws targeting pharma supply chain (Endpoints)
• FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes (FDA)
• They Followed Doctors’ Orders. Then Their Children Were Taken Away. (NYTimes)

• China's CSPC Pharma partners with Pfizer for oral COVID treatment (Reuters)
• Sanofi reaffirms target to deliver over $10.9 billion in annual vaccine sales by 2030 (Reuters)
• Sanofi says it's back to the drawing board on mRNA flu vaccines (Reuters)
• Touting programs from Novartis, Laekna bags $100M in Hong Kong IPO while Merck-partnered Kelun seeks up to $208M (Endpoints)
• Japan Mulls Pricing Changes, Generic Sector Review Amid Ongoing Shortages (Pink Sheet)
• WHO's cancer research agency to say aspartame sweetener a possible carcinogen -sources (Reuters)

• Alkermes wins battle against Sarissa in closely watched boardroom fight (Reuters)
• Preparing For FDA's Surprise Foreign Drug Inspection Regime (Law360)
• BioNTech, OncoC4 start late-stage lung cancer drug trial (Reuters)
• Gates Foundation to fund trial of long-awaited new tuberculosis vaccine candidate (STAT)
• AbbVie, Genmab's Epkinly shows promise in follicular lymphoma. Will FDA get on board? (Fierce)
• FDA issues warning to wholesaler sued by Gilead and J&J for distributing counterfeit medicines (STAT)
• Drug wholesaler owner indicted for alleged role in diverting Gilead and J&J HIV medicines (STAT)
• Counter-culture or pharma: Group behind MDMA therapy for PTSD wrestles with its identity (STAT)
• The cancer drug shortage isn’t new — and neither are the solutions: ‘It’s like Groundhog Day’ (STAT)
• Fujifilm Diosynth names Lars Petersen to replace Martin Meeson as CEO (Endpoints)
• Eiger BioPharmaceuticals to focus on GLP-1 candidate, cut workforce by 25% (Endpoints)
• ICER taps new president as Steve Pearson announces plans to step down (Endpoints)
• Meet ‘Fanzor,’ a cousin of CRISPR and Feng Zhang’s new gene editing tool (Endpoints)
• With just one response in 47 patients, Foghorn stops work on lead candidate in advanced eye cancer (Endpoints)
• Eton handed second CRL for methanol poisoning treatment (Endpoints)
• With approval supplement on deck, Reata dives into launch of its first commercial product Skyclarys (Fierce)

• Manufacturers Of Annex XVI Non-Clinical Devices Get Extra Time (MedtechInsight)
• Roche nabs FDA nod for another pair of CSF biomarker tests for Alzheimer's disease (Fierce)
• International Harmonization: Industry Needs To Take The Lead, MEDIcept’s Trautman Says (MedtechInsight)

• Trump demands the U.S. pay no more for drugs than other countries … again (STAT)
• Judge Says Pharma Industry Has 'Perverted' Hatch-Waxman (Law360)
• Ex-Pfizer employee charged with illegal trading based on unreleased Covid pill trial data (CNBC)
• Regenxbio, UPenn file patent suit against Sarepta related to new Duchenne gene therapy (Endpoints)